Andrew Ambrosy to Disease Progression
This is a "connection" page, showing publications Andrew Ambrosy has written about Disease Progression.
Connection Strength
1.385
-
A Natural Language Processing-Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Netw Open. 2021 11 01; 4(11):e2135152.
Score: 0.750
-
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2016 Mar; 18(3):306-13.
Score: 0.123
-
Effect of minor liver function test abnormalities and values within the normal range on survival in heart failure. Am J Cardiol. 2015 Apr 01; 115(7):938-41.
Score: 0.117
-
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012 Mar; 14(3):302-11.
Score: 0.096
-
Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020. Am J Cardiol. 2022 11 15; 183:129-136.
Score: 0.050
-
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study. BMJ Open. 2022 01 31; 12(1):e048755.
Score: 0.048
-
A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). J Cardiovasc Transl Res. 2020 08; 13(4):540-548.
Score: 0.041
-
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27; 69(25):3029-3039.
Score: 0.035
-
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017 04; 19(4):552-562.
Score: 0.033
-
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circ Heart Fail. 2016 09; 9(9).
Score: 0.033
-
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
Score: 0.032
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
Score: 0.026